May 2026 in “Pharmaceuticals” This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.
January 2024 in “Pharmaceutical medicine” In this study, most surveyed physicians were aware of the meningioma risk linked to cyproterone acetate monotherapy, but many did not recall receiving updated safety communications.
June 2026 in “Pharmaceuticals” This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.
Using data from the FDA's adverse event reporting system, this study identified 59 drugs linked to reduced male semen quality, with finasteride, dutasteride, and tamsulosin among the most frequently reported.
This study formulated an herbal anti-dandruff shampoo powder using Nyctanthes arbortristis as the main ingredient, and found that it exhibited significant anti-dandruff properties, beneficial physicochemical characteristics, and promising in-vitro results compared to a marketed medicated product.
